The FDA approve esketamine nasal spray for severe depression
from Medical News Today
Regulators in the United States have recently approved a new prescription-only nasal spray for use against treatment-resistant depression. The Food and Drug Administration have just granted approval of the drug esketamine to the Johnson & Johnson company Janssen Pharmaceuticals Inc. The fast-acting nasal spray is for use in conjunction with an oral antidepressant in adults with treatment-resistant depression, note the federal agency.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063